Literature DB >> 6747011

Changes in bone histoquantitative parameters and histochemical staining reactions for aluminium in a group of patients with chronic renal failure following a reduction in the aluminium concentration of the haemodialysis fluid.

J McClure, N L Fazzalari, R G Fassett, P G Pugsley.   

Abstract

Bone biopsies from a group of 16 patients in chronic renal failure treated by intermittent haemodialysis were available for histoquantitative and histochemical assessment before and after the introduction of reverse osmosis treatment of the dialysis fluid. This treatment reduced the aluminium concentration of the fluid from 1.15 mg/l to less than 0.06 mg/l. After the changeover there was an increase in the extent of calcification fronts. Overall, there was a decrease in the histochemical staining reactions for aluminium, although a few cases showed increased reactions. A large percentage of cases showing decreased reactions also had decreased osteoid volumes. It is concluded that reduction of the concentration of aluminium in the dialysis fluid is associated with an improvement in mineralisation state, and this is further evidence of the importance of minimising the aluminium burden of patients with chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6747011      PMCID: PMC498802          DOI: 10.1136/jcp.37.7.743

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  The demonstration of aluminum in animal tissues.

Authors:  D A IRWIN
Journal:  AMA Arch Ind Health       Date:  1955-08

2.  Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis.

Authors:  M M Platts; G C Goode; J S Hislop
Journal:  Br Med J       Date:  1977-09-10

3.  Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation.

Authors:  H A Ellis; J H McCarthy; J Herrington
Journal:  J Clin Pathol       Date:  1979-08       Impact factor: 3.411

4.  Bone histoquantitative findings and histochemical staining reactions for aluminium in chronic renal failure patients treated with haemodialysis fluids containing high and low concentrations of aluminium.

Authors:  J McClure; N L Fazzalari; R G Fassett; D J Pugsley
Journal:  J Clin Pathol       Date:  1983-11       Impact factor: 3.411

5.  Demonstration of calcification fronts by in vivo and in vitro tetracycline labelling.

Authors:  J McClure
Journal:  J Clin Pathol       Date:  1982-11       Impact factor: 3.411

6.  Disorders of bone and fracture of the femoral neck. Evaluation of computer image analysis in diagnosis.

Authors:  J M Faccini; A N Exton-Smith; A Boyde
Journal:  Lancet       Date:  1976-05-22       Impact factor: 79.321

7.  Localisation of aluminium by histochemical and electron probe x-ray microanalytical techniques in bone tissue of cases of renal osteodystrophy.

Authors:  P S Smith; J McClure
Journal:  J Clin Pathol       Date:  1982-11       Impact factor: 3.411

8.  Detection and distribution of aluminium in bone.

Authors:  J Denton; A J Freemont; J Ball
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

9.  Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey.

Authors:  I S Parkinson; M K Ward; T G Feest; R W Fawcett; D N Kerr
Journal:  Lancet       Date:  1979-02-24       Impact factor: 79.321

10.  The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy.

Authors:  S M Ott; N A Maloney; J W Coburn; A C Alfrey; D J Sherrard
Journal:  N Engl J Med       Date:  1982-09-16       Impact factor: 91.245

  10 in total
  1 in total

1.  Demonstration of aluminium in iliac bone: correlation between aluminon and solochrome azurine staining techniques with data on flameless absorption spectrophotometry.

Authors:  H A Ellis; M M Pang; W H Mawhinney; A W Skillen
Journal:  J Clin Pathol       Date:  1988-11       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.